Inflammatory markers and cognition in well-functioning African-American and white elders

Background: Several lines of evidence suggest that inflammatory mechanisms contribute to AD. Objective: To examine whether several markers of inflammation are associated with cognitive decline in African-American and white well-functioning elders. Methods: The authors studied 3,031 African-American and white men and women (mean age 74 years) enrolled in the Health, Aging, and Body Composition Study. Serum levels of interleukin-6 (IL-6) and C-reactive protein (CRP) and plasma levels of tumor necrosis factor-α (TNFα) were measured at baseline; cognition was assessed with the Modified Mini-Mental State Examination (3MS) at baseline and at follow-up. Cognitive decline was defined as a decline of >5 points. Results: In age-adjusted analyses, participants in the highest tertile of IL-6 or CRP performed nearly 2 points lower (worse) on baseline and follow-up 3MS (p < 0.001 for all) and declined by almost 1 point over the >2 years (p = 0.01 for IL-6 and p = 0.04 for CRP) compared with those in the lowest tertile. After multivariate adjustment, 3MS scores among participants in the highest tertile of IL-6 and CRP were similar at baseline but remained significantly lower at follow-up (p ≤ 0.05 for both). Those in the highest inflammatory marker tertile were also more likely to have cognitive decline compared with the lowest tertile for IL-6 (26 vs 20%; age-adjusted odds ratio [OR] = 1.34; 95% CI 1.06 to 1.69) and for CRP (24 vs 19%; OR = 1.41; 95% CI 1.10 to 1.79) but not for TNFα (23 vs 21%; OR = 1.12; 95% CI 0.88 to 1.43). There was no significant interaction between race and inflammatory marker or between nonsteroidal anti-inflammatory drug use and inflammatory marker on cognition. Conclusions: Serum markers of inflammation, especially IL-6 and CRP, are prospectively associated with cognitive decline in well-functioning elders. These findings support the hypothesis that inflammation contributes to cognitive decline in the elderly.

[1]  J. M. Guralnik,et al.  Drug data coding and analysis in epidemiologic studies , 1994, European Journal of Epidemiology.

[2]  Oscar L. Lopez,et al.  Evaluation of Dementia in the Cardiovascular Health Cognition Study , 2003, Neuroepidemiology.

[3]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[4]  J W Rowe,et al.  Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging , 2002, Neurology.

[5]  R. Schmidt,et al.  Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study , 2002, Annals of neurology.

[6]  M. Lawton,et al.  C-Reactive Protein Levels and Viable Chlamydia pneumoniae in Carotid Artery Atherosclerosis , 2001, Stroke.

[7]  I. Mackenzie.  Postmortem studies of the effect of anti-inflammatory drugs on Alzheimer-type pathology and associated inflammation , 2001, Neurobiology of Aging.

[8]  P. Grammas,et al.  Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease , 2001, Neurobiology of Aging.

[9]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[10]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[11]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[12]  P. Mcgeer,et al.  Brain inflammation in Alzheimer disease and the therapeutic implications. , 1999, Current pharmaceutical design.

[13]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[14]  V. Singh,et al.  Circulating cytokines in Alzheimer's disease. , 1997, Journal of psychiatric research.

[15]  T. Duong,et al.  C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer's disease , 1997, Brain Research.

[16]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[17]  L. Fernández-Novoa,et al.  Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease , 1996 .

[18]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[19]  L. Fernández-Novoa,et al.  Blood levels of histamine, IL-1 beta, and TNF-alpha in patients with mild to moderate Alzheimer disease. , 1996, Molecular and chemical neuropathology.

[20]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[21]  W. Banks,et al.  Permeability of the blood-brain barrier to soluble cytokine receptors. , 1995, Neuroimmunomodulation.

[22]  D. Cucinotta,et al.  Acute Phase Reactant α1Antichymotrypsin Is Increased in Cerebrospinal Fluid and Serum of Patients with Probable Alzheimer Disease , 1995, Alzheimer disease and associated disorders.

[23]  H J Cohen,et al.  Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. , 1994, American journal of clinical pathology.

[24]  L. Mucke,et al.  Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[25]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[26]  L. Radloff.  The CES-D Scale , 1977 .